Abstract

You have accessJournal of UrologyProstate Cancer: Detection and Screening II1 Apr 2015MP60-07 CONFIGURATION AND VALIDATION OF A NOVEL PROSTATE DISEASE NOMOGRAM PREDICTING PROSTATE BIOPSY OUTCOME: A PROSPECTIVE STUDY CORRELATING CLINICAL INDICATORS AMONG FILIPINO ADULT MALES WITH ELEVATED PSA LEVEL Michael Chua, Patrick Tanseco, Jonathan Mendoza, Josefino Castillo, Marcelino Morales, and Saturnino Luna Michael ChuaMichael Chua More articles by this author , Patrick TansecoPatrick Tanseco More articles by this author , Jonathan MendozaJonathan Mendoza More articles by this author , Josefino CastilloJosefino Castillo More articles by this author , Marcelino MoralesMarcelino Morales More articles by this author , and Saturnino LunaSaturnino Luna More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2209AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To configure and validate a novel prostate disease nomogram providing prostate biopsy outcome probabilities from a prospective study correlating clinical indicators and Prostate specific antigen (PSA) derivatives among Filipino adult male with elevated serum total PSA level. METHODS A prospective study of all men with an elevated serum total PSA underwent initial prostate biopsy at a tertiary institution from January 2011 to August 2014. Clinical indicators, diagnostic parameters, PSA level and PSA derivatives, were collected and considered as predictive factors for biopsy outcome. Multiple logistic regression analysis involving a backward elimination selection procedure was used to select independent predictors. A nomogram model was developed that was based on independent predictors to calculate the probability of the biopsy outcomes. A receiver-operating characteristic (ROC) curve was used to assess the accuracy of the nomogram and PSA levels alone in predicting differential biopsy outcome. External validation of the nomogram was done using separate set of patients' data from another center for determination of sensitivity and specificity. The protocol of this study was reviewed and approved by the Institutional Scientific Review Board (ISRB), Institutional Ethics Review Board (IERB), and registered at Clinicaltrial.gov (Identifier: NCT01826617) RESULTS A total of 552 patients were referred to our institution for initial prostate biopsy. 191 (34.6%) patients had benign prostatic hyperplasia, 165 (30%) had prostatitis, particularly chronic type. The remaining 196 patients (35.5%) had prostate adenocarcinoma. Number of patients according to Gleason scoring classification of the prostate cancer ≥8, 7 and 6, were 82 (42%), 66 (33.7%), 48 (24.5), respectively. The significant independent variables used to predict biopsy outcome were age, family history of prostate cancer, prior prostatitis, PSA level, PSA density, PSA velocity, echogenic findings on ultrasound and DRE status. The areas under the ROC curve for prostate cancer using PSA alone and the nomogram were 0.688 and 0.804, respectively. CONCLUSIONS The nomogram configured based on routinely available clinical parameters and PSA derivatives, provides high predictive accuracy with good performance characteristics in predicting the prostate biopsy outcome such as presence of prostate cancer, high Gleason prostate cancer, benign prostatic hyperplasia and chronic prostatitis. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e740 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Chua More articles by this author Patrick Tanseco More articles by this author Jonathan Mendoza More articles by this author Josefino Castillo More articles by this author Marcelino Morales More articles by this author Saturnino Luna More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call